For any subsequent applicable periods that the generic Part D rebatable drug or biosimilar appears as currently in shortage, CMS would reduce the total rebate amount in accordance with the drug shortages reduction proposed in 428.301, starting with the highest reduction (that is, 75 percent for a generic Part D rebatable drug or plasma-derived product and 25 percent for a Part D rebatable drug that is not a generic drug or plasma-derived product)
For further information on the DPP model test, [338] the CDC's National DPP, [339] and DPRP Standards, [340] please refer to the CY 2017 (81 FR 80471) and CY 2018 PFS (82 FR 52976) final rules and related websites
Youll have life insurance at standard health class, just like predominantly all the other carriers
On October 16, 2023, we updated the JW Modifier and JZ Modifier Policy FAQ document to include the requirement of the JZ modifier by the supplier
Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2019